08:30-08:50 | Registration |
08:50-09:00 | Opening Remark |
| Session I-1.NGS 좌장 : ?건?(??센?? | Session I-2. Lung cancer genomics좌장 : ?세?(?산??) |
---|
09:00-09:20 | NGS기반 ?전???널검?의 질??span>????(?성?전??구?? | 09:00-09:30 | NGS data -based Artificial Intelligence Model for Cancer-Drug-Response Profiling ?종??(?테?바이?? |
09:20-09:40 | NGS 기반 ?전???널 검??급여??배경 ??망?효??(?세??) | 09:30-10:00 | Study for cancer genomics; whats left?김주한 (?울?) |
09:40-10:00 | NGS 기반 ?전???널 검?의 기???황 ??망 I김지??(?산??) | 10:00-10:30 | Genomic data sharing; implications & hurdles?연준(가?릭??) |
10:00-10:20 | NGS 기반 ?전???널 검?의 기???황 ??망 II김?정 (가?릭??) | |
10:20-10:30 | Q&A | |
10:30-11:00 | Coffee Break |
| Plenary Session 좌장 : 조문준 (충남??) |
---|
11:00-11:50 | The Healthcare Innovation for the precision cancer medicine with IBM Watson Health? Annette Hicks (Watson Health, IBM) |
11:50-12:00 | Q&A |
| Luncheon Symposium I좌장 : 김?위 (?산??) |
---|
12:00-12:40 | Big Stride in 1L NSCLC treatment: moving from chemotherapy to anti- PD 1 therapy (MSD)Raffaele Califano (The Christie NHS Foundation Trust and University Hospital of South Manchester) |
12:40-13:00 | Coffee Break |
| Oral Presentation |
---|
13:00~13:10 | Chemopreventive effect of long-term use of low-dose aspirin on lung cancer risk A nationwide study considering competing risk 천??(?화??) | 13:00~13:10 | Weekly Docetaxel as first-line chemotherapy in elderly patients with advanced squamous cell non-small cell lung cancer : phase II study 최종??(고려??) | 13:00~13:10 | ?암 ?자???으?개인 맞춤???흡 ?활 ?비???튼 PHR®)???상???과??인?기 ?한 ?향???구 지?? (?산??) |
13:10~13:20 | Bone Metastasis is associated with Osteoporosis Risk Among Lung Cancer Patients ?승?(고려??) | 13:10~13:20 | Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer 박송??(?균관??) | 13:10~13:20 | Generative Model of Functional RT-Plan Chest CT for Lung Cancer Patients Using Machine Learning Algorithm ?범??(?울??) |
13:20~13:30 | Role of low-dose computerized tomography in lung cancer screening among never-smokers 강혜?(?울??) | 13:20~13:30 | Clinical characteristics of lung cancer with programmed death-ligand 1 expression 박하??(?남??) | 13:20~13:30 | Generation of predicted tumor-regression computed tomography image during definitive concurrent chemo-radiotherapy of the lung cancer using deep learning technique 김경수 (?남권원?력?학?? |
13:30~13:40 | Comparison of PD-L1 Expression on Cell Block and Matched Resection Specimens from Lung Cancer ????(?아??) | 13:30~13:40 | Continuing Gefitinib beyond progression in patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A phase II single-arm prospective trial ?성??(?균관??) | 13:30~13:40 | Initial PET/CT maximal SUV as a Biologic Predictive Factor Prognostic of Outcome in Early-stage NSCLC after SABR 곽유?(가?릭??) |
13:40~13:50 | Extracellular vesicle DNA for liquid biopsy ?재??(건국??) | 13:40~13:50 | Outcomes of T790M+ lung cancer patients treated with osimertinib in real world practice after acquired resistance to the previous EGFR-TKI in Korea ?동?(?산??) | 13:40~13:50 | Exosomes Increase More at Pulmonary Vein than Peripheral Vessel in Lung Cancer: based on preclinical and clinical studies 김?구 (고려??) |
13:50~14:00 | Detection and dynamic change of EGFR mutation status in plasma and comparison of tissue from NSCLC patients ?윤?(?산??) | 13:50~14:00 | Phase II Trial of AZD9291 in Second-Line Treatment after Acquired Resistance with T790M Mutation Detected From Circulating Tumor DNA (LiquidLung-O-Cohort 2) 김?철 (?남??) | 13:50~14:00 | Prognostic Factor and Survival of Patients with Resected stage IIIA N2 Lung Adenocarcinoma 김?훈 (?산??) |
14:00~14:10 | Feasibility and alternative approaches of rebiopsy in non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitors 김?정 (건국??) | 14:00~14:10 | Tumor-derived microvesicles promote the immune surveillance of tumor through PD-1/PD-L1 interaction 김?하 (?산??) | 14:00~14:10 | Feasibility of lobectomy and mediastinal node dissection by video-assisted thoracoscopic surgery following neoadjuvant?chemoradiaotherapy for stage IIIA N2?lung cancer: Propensity matching analysis ?영??(?균관??) |
14:10~14:20 | Feasibility of Liquid Biopsy Using Plasma and Platelets for Detection of ALK Rearrangements in Non-Small Cell Lung Cancer 박철?(?남??) | 14:10~14:20 | Glucose Supports EGFR-mutant Lung Adenocarcinoma Cell Survival by Inhibiting Autophagy-mediated EGFR Degradation ?진?(?산??) | 14:10~14:20 | Diffusing capacity(DLco) decrement following neoadjuvant concurrent chemoradiotherapy :implication on postoperative pulmonary complications in lung cancer patients ?수?(?균관??) |
14:20-14:40 | Coffee Break |
| Session II-1. In-depth review of 8th TNM staging 좌장 : ?춘??(?울??) | Session II-2. Screen-detected Ground Glass Nodules좌장 : ?국?(?남??) | Session II-3. Emerging field of Radiomics 좌장 : ?환??(고려??) |
---|
14:40-15:05 | TNM staging; pulmonologists perspective?보?(??센?? | 14:40-15:00 | Management strategy and guideline: follow-up vs. surgery?재??(??센?? | Basics of image processing in radiomics 김?국 (?산??) |
15:05-15:30 | TNM staging; radiologists perpective?명??(가?릭??) | 15:00-15:20 | Preoperative workup: Bronchoscopy/EBUS, brain MRI, PET/ CT, Biopsy are needed?조정??(부?의?) | Radiomics: the current status?호??(?균관??) |
15:30-15:55 | TNM staging; surgeons perspective?진?(?세??) | 15:20-15:40 | Localization technique조석?(?울??) | Radiomics and beyond: limitations and future directions박창?(?울??) |
15:55-16:10 | Q&A | 15:40-16:00 | Surgical procedure: Optimal extent of pulmonary resection and mediastinal LN assessment김?? (?균관??) | Q&A |
16:00-16:10 | Q&A | |
16:10-16:40 | Coffee Break |
| Session III-1. Neuroendocrine tumors other than SCLC좌장 : 김관?(?울??) | Session III-2. Thymic Epithelial Tumors 좌장 : ?영??(?주??) | Session III-3. SCLC
좌장 : ?명?(?균관??) |
---|
16:40-17:00 | Pathology of neuroendocrine tumor?승??(가천의?) | Review of staging and pathologic classification????(?아??) | Novel chemotherapeutic agent in SCLC김?련 (?세??) |
17:00-17:20 | Surgery김?렬 (?산??) | Recent updates of chemotherapy?희?(가천의?) | Role of radiation therapy in extensive disease SCLC김?재 (?울??) |
17:20-17:40 | Chemotherapy for large cell neuroendocrine carcinoma?종?(?균관??) | Radiotherapy for Thymic Tumors?상??(강원??) | Role of surgery in SCLC?호??(부?의?) |
17:40-18:00 | Coffee Break |
| Dinner Symposium (Sapphire room)좌장 : 김?철 (?남??) |
---|
18:00-18:50 | Recent update with clinical practice of Atezolizumab in NSCLC (Roche)????(??센?? |